ZipLine Medical, Inc. was selected as a winner of the Red Herring Top 100 North America award, which recognizes the continent’s most exciting and innovative private technology companies.

Winners were chosen from thousands of entrants in a gamut of verticals, from financial technology to marketing, and medical devices to Internet of things. Companies were judged by industry experts, insiders and journalists on a wide variety of criteria, including financial performance, innovation, business strategy, and market penetration. Red Herring’s editors have been evaluating the world’s startups and tech companies for over two decades and their insights enable them to select firms that will continue on a trajectory to success. Brands such as Alibaba, Google, Kakao, Skype, Spotify, Twitter and YouTube have all been singled out as Red Herring winners in the past.

The Zip® Surgical Skin Closure and PreLoc Wound Closure devices have seen significant adoption in key surgical procedures such as total joint replacement and limb salvage. In addition to the economic benefits these devices provide to the hospital and clinic, the high degree of patient satisfaction they engender has created word of mouth that often drives a patient’s friends and family to request ZipLine devices for their next surgery.

“Adoption of the Zip device in our procedures represents the cutting edge of surgery. Orthopedic patients are becoming more and more educated on the products and techniques that offer the best surgical outcomes, and come to the table expecting these from their surgeon,” said Robert C. Marchand MD, orthopedic surgeon and robotic joint replacement expert in Wakefield, Rhode Island. “The Zip enables us to provide patients with a more comfortable recovery and better cosmetic outcome while reducing surgical procedure time and patient complications that add costs to the healthcare system.

Latest news

MVM invests in Nalu Medical
February 17, 2022

CARLSBAD, Calif. (PRWEB) February 17, 2022 Nalu Medical, Inc. (“Nalu”), a private company focused on innovative and minimally invasive solutions for […]

Clarivate acquires Patient Connect
December 22, 2021

 Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced that […]

MVM invests in Vero Biotech
December 15, 2021

VERO Biotech Inc., a fast-growing commercial business dedicated to improving the lives of patients through innovative technologies, today announced the […]

MVM Invests In Optinose
November 18, 2021

MVM invested $20 million in Optinose. Optinose markets XHANCE, an innovative drug delivery system that delivers steroids high and deep […]

Paragon 28, Inc. Announces Pricing of Initial Public Offering
October 15, 2021

ENGLEWOOD, Colo., Oct. 15, 2021 /PRNewswire/ — Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and […]

MVM invests in InBrace
September 8, 2021

MVM invested $15 million in InBrace. InBrace is an orthodontic company that created the novel SmartwireTM, a new category in […]

Valneva Announces Positive Phase 3 Pivotal Results for its Single-Shot Chikungunya Vaccine Candidate
August 6, 2021

Saint Herblain (France), August 5, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the […]

Vertos mild® Patients Demonstrate Durable 5 Year Outcomes
May 18, 2021

Most Minimally Invasive Lumbar Decompression (mild®) providers are very familiar with the 1-year study conducted by Nagy Mekhail, MD, PhD […]

Valneva Announces the Pricing of its Initial Public Offering on Nasdaq
May 11, 2021

Saint-Herblain (France), May 6, 2021  – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for […]

eXmoor pharma secures £12m ($17m) from healthcare investment firm MVM marking milestone towards significant expansion plans
March 16, 2021

eXmoor, the expert cell and gene therapy (CGT) services company (Bristol, England), has announced an initial investment of £12m ($17m) […]